SCHEMBL2180879

SCHEMBL2180879

Clc1ccc(-c2nc3cccnn3c2Cn2cncn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 9/20 0.42
▸ PDE4B Q07343 9/20 0.42
▸ PDE4C Q08493 9/20 0.42
▸ PDE4D Q08499 9/20 0.42
▸ CYP19A1 P11511 4/20 0.41
▸ KDM4E B2RXH2 5/20 0.39
▸ MAPK13 O15264 1/20 0.39
▸ MAPK12 P53778 1/20 0.39
▸ MAPK11 Q15759 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ SLC2A1 P11166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1430574 0.81 KDM4E (0.61) KDM4EPOLBHTTNPC1RAB9A
Hydrochloric Acid SCHEMBL1430456 0.81 PDE4B (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL1431134 0.78 SLC2A1 (0.59) PDE4DKDM4EHTTSLC2A1
SCHEMBL1432526 0.74 SLC2A3 (0.53) CYP19A1KDM4EHTTSLC2A1
SCHEMBL1429299 0.73 PDE4B (0.44) PDE4APDE4BPDE4CPDE4DMAPK13
SCHEMBL1431341 0.72 SIRT5 (0.54) CYP19A1KDM4EHTTSLC2A1
SCHEMBL1430303 0.71 PDE4B (0.48) PDE4APDE4BPDE4CPDE4DMAPK13
SCHEMBL1430136 0.71 PDE4B (0.46) PDE4APDE4BPDE4CPDE4DMAPK13
SCHEMBL1430606 0.70 PDE4B (0.44) PDE4APDE4BPDE4CPDE4DMAPK13
Hydrochloric Acid SCHEMBL11358575 0.70 CYP19A1 (0.67) CYP19A1KDM4EPOLBHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 — — US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 — — US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD PDE4A 216/4885PDE4B 230/4885PDE4C 347/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD PDE4A 216/4885PDE4B 230/4885PDE4C 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback